A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer (NCT04516447)
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.
Who can join: Review the eligibility criteria below.
Location: Site 0264 — Aurora, Colorado
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (24 Sites)
- Site 0264 — Aurora, Colorado
- Site 0104 — Boston, Massachusetts
- Site 0111 — St Louis, Missouri
- Site 0173 — New York, New York
- Site 0259 — Durham, North Carolina
- Site 0191 — Providence, Rhode Island
- Site 0196 — Nashville, Tennessee
- Site 0103 — Houston, Texas
- Site 2707 — South Brisbane, Queensland
- Site 2708 — Sunshine Coast, Queensland
- Site 2709 — Adelaide, South Australia
- Site 2716 — Melbourne, Victoria
- Site 2706 — Melbourne, Victoria
- Site 2705 — Nedlands, Western Australia
- Site 1001 — Banja Luka,
- Site 1002 — Sarajevo,
- Site 1003 — Tuzla,
- Site 1202 — Panagyurishte,
- Site 1201 — Sofia,
- Site 1401 — Tbilisi,
- Site 1902 — Belgrade,
- Site 2901 — Busan,
- Site 2903 — Seoul,
- Site 2904 — Seoul,
📞 Contact the Study Coordinator
Phone: (858) 263-4333
Email: medicalaffairs@zentalis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Solid Tumor
- A Safety And Efficacy Study Of HLA-G- Targeted CAR-T Cells IVS-3001 In Subjects With Previously Treated Advanced HLA-G-Positive Solid Tumors — Houston, Texas
- A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer — Middletown, New Jersey
- A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer — Basking Ridge, New Jersey
- Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid Tumors — Chicago, Illinois
- A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors — New York, New York
- Concurrent Azeliragon With Craniospinal Irradiation — New York, New York
Explore by condition: All Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.